TW202333775A - 一種穩定的受體激動劑的醫藥組成物、製備方法及其應用 - Google Patents

一種穩定的受體激動劑的醫藥組成物、製備方法及其應用 Download PDF

Info

Publication number
TW202333775A
TW202333775A TW112101047A TW112101047A TW202333775A TW 202333775 A TW202333775 A TW 202333775A TW 112101047 A TW112101047 A TW 112101047A TW 112101047 A TW112101047 A TW 112101047A TW 202333775 A TW202333775 A TW 202333775A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
buffer
active ingredient
osmotic pressure
pressure regulator
Prior art date
Application number
TW112101047A
Other languages
English (en)
Chinese (zh)
Inventor
董禮
韓顏
郝好華
余俊
宋陽
Original Assignee
大陸商江蘇豪森藥業集團有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇豪森藥業集團有限公司 filed Critical 大陸商江蘇豪森藥業集團有限公司
Publication of TW202333775A publication Critical patent/TW202333775A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW112101047A 2022-01-10 2023-01-10 一種穩定的受體激動劑的醫藥組成物、製備方法及其應用 TW202333775A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210021736 2022-01-10
CN2022100217361 2022-01-10

Publications (1)

Publication Number Publication Date
TW202333775A true TW202333775A (zh) 2023-09-01

Family

ID=87073306

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112101047A TW202333775A (zh) 2022-01-10 2023-01-10 一種穩定的受體激動劑的醫藥組成物、製備方法及其應用

Country Status (10)

Country Link
US (1) US20250170218A1 (https=)
EP (1) EP4464331A4 (https=)
JP (1) JP2024545887A (https=)
KR (1) KR20240135785A (https=)
CN (1) CN118488848A (https=)
AU (1) AU2023205290A1 (https=)
CA (1) CA3242599A1 (https=)
MX (1) MX2024007861A (https=)
TW (1) TW202333775A (https=)
WO (1) WO2023131325A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12102664B2 (en) * 2023-12-27 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating endocrine diseases and disorders
US12290550B1 (en) 2023-12-27 2025-05-06 Olfactive Ai, Inc. Compositions and methods for treating endocrine diseases and disorders
WO2025191149A1 (en) * 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
WO2026007980A1 (zh) * 2024-07-03 2026-01-08 上海海雁医药科技有限公司 一种mor受体激动剂的液体组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101366692A (zh) * 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
AU2013205144B2 (en) * 2008-06-17 2015-07-16 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN112351994B (zh) * 2019-04-11 2024-06-07 江苏豪森药业集团有限公司 一种多受体激动剂及其医药用途
CN111825758B (zh) * 2019-04-19 2024-11-22 上海翰森生物医药科技有限公司 Glp-1和gip共激动剂化合物
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
CN113383014B (zh) * 2019-11-15 2024-06-18 江苏豪森药业集团有限公司 双受体重激动剂化合物及其药物组合物
EP4110800A1 (en) * 2020-03-06 2023-01-04 Sanofi Peptides as selective gip receptor agonists
CN114349828B (zh) * 2020-11-27 2023-12-08 江苏师范大学 Glp-1/胰高血糖素受体双重激动剂及其应用

Also Published As

Publication number Publication date
CN118488848A (zh) 2024-08-13
EP4464331A4 (en) 2025-05-07
CA3242599A1 (en) 2023-07-13
US20250170218A1 (en) 2025-05-29
MX2024007861A (es) 2024-07-09
JP2024545887A (ja) 2024-12-13
AU2023205290A1 (en) 2024-07-11
WO2023131325A1 (zh) 2023-07-13
KR20240135785A (ko) 2024-09-12
EP4464331A1 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
TW202333775A (zh) 一種穩定的受體激動劑的醫藥組成物、製備方法及其應用
TW201100093A (en) Preparation comprising insulin, nicotinamide and an amino acid
JP2024545887A5 (https=)
CN109640955B (zh) 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
EP4591875A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
US20230285326A1 (en) Epinephrine formulations
CN110693861A (zh) 一种硫酸特布他林雾化吸入用溶液制剂及其制备方法
US12343383B2 (en) High concentration insulin formulation
EP3811948B1 (en) Glycosides for use in preventing and treating diabetic complications
CN116270980A (zh) 一种含glp-1类似物的药物组合物及其制备方法
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
TWI857310B (zh) 酮咯酸胺丁三醇的液體組合物、其製備方法及應用
CN114848650B (zh) 一种稳定的艾司唑仑制剂组合物及其制备方法
WO2026013454A1 (en) Multi-dose pen of tirzepatide
WO2019046952A1 (en) SUBCUTANEOUS PHARMACEUTICAL PREPARATION COMPRISING INSULIN (S) AND ANTI-INFLAMMATORY AGENT FOR REDUCING TISSUE INFLAMMATORY RESPONSE IN DIABETIC PATIENTS
WO2025190304A1 (zh) 包含glp-1和gip双受体激动剂的药物组合物及其用途
WO2025113170A1 (zh) 含有glp-1受体激动剂的经鼻给药的组合物及其制备方法与用途
CA2685636C (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin
CN117771347A (zh) Glp-1类似物与胰岛素类似物药物组合物制剂及其制备方法和应用
HK40020222A (en) Terbutaline sulfate solution preparation for aerosol inhalation and preparation method thereof
CN116407614A (zh) 一种新型三激动剂创新生物药物的稳定制剂
HK40000201B (zh) 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN120641091A (zh) (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗糖尿病和前驱糖尿病中的用途
HK40000201A (en) Pharmaceutical preparation containing polyethylene gylcol loxenatide and preparation method thereof
WO2017164776A1 (ru) Фармацевтическая композиция глибенкламида в форме раствора для инъекций, способ ее получения и способ получения препарата глибенкламида